Ozempic Might Be Much less Efficient for Emotional Eaters, Research Suggests

GLP-1 agonists—so-called “wonder medicine” like Ozempic or Wegovy that assist people decrease blood sugar ranges and shed pounds, amongst different issues—yield important outcomes for some sufferers, however not all. Individuals’s motivations to overeat could play a task on this, in line with a brand new examine.

To analyze why some folks don’t profit from GLP-1 agonists as a lot as others, researchers noticed 92 members with sort 2 diabetes in Japan throughout their first yr of taking GLP-1 medicine. Their results, printed at the moment in Frontiers in Medical Diabetes and Healthcare, recommend that individuals who overeat as a consequence of exterior causes—such because the sight or scent of scrumptious meals—had higher probabilities of responding effectively to the medicine in the long run than individuals who overeat for emotional causes.

Who will profit most from GLP-1 medicine?

“Pre-treatment evaluation of consuming conduct patterns could assist predict who will profit most from GLP-1 receptor agonist remedy,” Daisuke Yabe, senior creator of the examine and a professor of diabetes, endocrinology, and diet at Kyoto College, stated in a Frontiers assertion. “GLP-1 receptor agonists are efficient for people who expertise weight acquire or elevated blood glucose ranges as a consequence of overeating triggered by exterior stimuli. Nonetheless, their effectiveness is much less anticipated in instances the place emotional consuming is the first trigger.”

The group revealed this by gathering information on the members’ physique weight and composition, weight-reduction plan, and data reminiscent of blood glucose, levels of cholesterol, and relationship with meals initially of the therapy, three months after, and one yr after. They targeted on emotional consuming (consuming in response to detrimental feelings), exterior consuming (consuming as a result of the meals seems to be good), and restrained consuming (controlling one’s weight-reduction plan to shed pounds). Whereas it might sound contradictory, extreme restrained consuming can really end in disordered consuming, in line with the researchers.

Over the yr, the members skilled a statistically important lack of physique weight and lowered levels of cholesterol and physique fats share with out altering skeletal muscle mass. Whereas blood glucose ranges ameliorated, the advance wasn’t statistically important. There have been, nevertheless, some variations relying on consuming behaviors. Three months after the beginning of the therapy, members reported extra restrained consuming and fewer exterior or emotional consuming. By the tip of the yr, although, members had returned to their unique restrained and emotional consuming habits.

“One potential clarification is that emotional consuming is extra strongly influenced by psychological elements which might not be instantly addressed by GLP-1 receptor agonist remedy,” stated Takehiro Kato, second creator of the article and a researcher from Gifu College, “People with outstanding emotional consuming tendencies could require further behavioral or psychological assist.”

Exterior consuming lessened over the yr of therapy

Contributors reported decreased exterior consuming all through all the yr, and people that claimed excessive ranges of exterior consuming initially of the therapy noticed the best advantages in blood glucose ranges and weight reduction. Alternatively, the group didn’t determine any affiliation between emotional or restrained consuming scores initially and drug advantages by the 12-month mark.

“Whereas our examine suggests a possible affiliation between exterior consuming conduct and therapy response to GLP-1 receptor agonists, these findings stay preliminary,” defined Yabe. What’s extra, the group’s examine was observational, and members self-reported info, that means the researchers revealed a possible affiliation, not a causation.

“Additional proof is important earlier than they are often carried out in scientific observe. Ought to future large-scale or randomized managed trials validate this relationship, incorporating easy behavioral assessments might grow to be a useful part in optimizing therapy methods,” Yabe concluded.